Latest news
Xenon Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 20:04:17 GMTXenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:34 GMTXENE: Raised 2026 guidance on strong Atera demand, robust consumables growth, and margin expansion - TradingViewTradingView · Thu, 06 Aug 2026 23:24:33 GMTXenon Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:01:41 GMTXenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMTXENE: Net loss rose to $213M in H1 2026 as R&D spending surged, with $1.25B in cash and investments - TradingViewTradingView · Thu, 06 Aug 2026 20:34:12 GMTXENE: Azetukalner NDA on track for Q3 2026; strong cash position supports ongoing late-stage trials - TradingViewTradingView · Thu, 06 Aug 2026 20:18:52 GMTXENE Q2'26 Earnings: EPS estimate is (1.14) USD - TradingViewTradingView · Wed, 05 Aug 2026 11:00:44 GMT